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Abstract
Background: Black-white disparities in breast cancer incidence rates and birth outcomes raise concerns about
potential disparities in the reproductive health of premenopausal breast cancer survivors. We examined the
prevalence of preterm birth (PTB), low birthweight (LBW), and small for gestational age (SGA) by breast cancer
history and effect modification by race.
Methods: We analyzed linked North Carolina birth records and Central Cancer Registry files from 1990 to 2009
(n = 2,325,229). We used multivariable negative log-binomial regression to calculate prevalence ratios (PRs) and
95% confidence intervals (CIs) for the association between breast cancer history and PTB, LBW, and SGA.
Results: Of 1,912,269 eligible births, 512 births were to mothers with a previous breast cancer diagnosis history.
Average age at breast cancer diagnosis was 31.8 years (SD = 4.7). Mean time from diagnosis to delivery was 3.3 years
(SD = 2.8). After multivariable adjustment, the PR was 1.67 (95% CI, 1.42–1.97) for PTB, 1.50 (95% CI, 1.23–1.84) for LBW,
and 1.30 (95% CI, 1.05–1.61) for SGA comparing women with a breast cancer history to the general population. Among
black mothers, the PRs associated with breast cancer history for PTB, LBW, and SGA were 1.31 (95% CI, 1.00–1.72), 1.49
(95% CI, 1.14–1.94), and 1.44 (95% CI, 1.11–1.87), respectively. The corresponding PRs among white mothers were 2.06
(95% CI, 1.67–2.54), 1.53 (95% CI, 1.12–2.08), and 1.10 (95% CI, 0.77–1.58), respectively. The interaction between breast
cancer history and race was statistically significant for associations with PTB, but not for LBW or SGA.
Conclusions: In our data, women with a breast cancer history were at higher risk of delivering a PTB, LBW, or SGA
infant, especially if they received chemotherapy or gave birth within 2 years of their breast cancer diagnosis date.
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Background
With an increasing number of women delaying child-
bearing [1, 2] and improved breast cancer survival
among women diagnosed before the age of 50 years [3],
many young breast cancer patients face decisions at the
time of diagnosis that may influence their future repro-
ductive health. Beyond the risk of infertility [4–7], other
adverse birth outcomes including preterm birth (PTB),
low birthweight (LBW), and small for gestational age
(SGA) may be more common among women with a
prior breast cancer history [8]. The potential risk of
adverse birth outcomes among breast cancer survivors
has not been studied in the context of existing racial dis-
parities in breast cancer incidence and birth outcomes in
the USA.
Black women are more likely than their white counter-
parts to be diagnosed with breast cancer during their repro-
ductive years [9] and deliver PTB, LBW, or SGA infants.
Breast cancer diagnosed in young women, especially young
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black women, is more likely to be more aggressive and
have a poorer prognosis than breast cancer diagnosed
in older women and young white women [10–12]. In
the general USA population, 9.6% of infants are deliv-
ered preterm (PTB; <37 weeks gestation) and 8.1% have
a low birthweight (LBW; <2500 g) [2]. Rates of PTB,
LBW, and SGA (i.e., sex-specific birthweight below the
tenth percentile for gestational age) increase with maternal
age and vary by race/ethnicity. For example, mothers aged
45 years or older compared to those aged 25–34 years have
a higher portion of PTB (24.2 vs. 9.1%) and LBW (20.4 vs.
7.4%) deliveries [13]. Compared to white women, black
women are 41% more likely to deliver a PTB infant, 63%
more likely to deliver a LBW infant [2], and two to three
times more likely to deliver a SGA infant [14, 15].
Breast cancer diagnosis and its treatment may have
long-lasting effects on reproductive health outcomes.
Alkylating agent-based chemotherapies can cause ovarian
toxicity [5], including loss of mature ovarian follicles. Dur-
ing chemotherapy treatment, premenopausal women may
experience temporary chemotherapy-related amenorrhea
or premature ovarian failure [4–7]. After completion of
chemotherapy, a 5- to 10-year course of adjuvant endocrine
therapy is recommended for hormonally responsive tumors
to improve relapse-free and overall survival [6, 7, 16]. Preg-
nancy is not recommended during the course of adjuvant
endocrine therapy; therefore, some women may choose to
not initiate or to interrupt endocrine therapy to achieve
pregnancy [17].
Black-white disparities in breast cancer incidence rates
and birth outcomes raise concerns about potential dis-
parities in the reproductive health of premenopausal
breast cancer survivors. Most previous studies have
focused on survival rates among breast cancer survivors
with a post-diagnosis pregnancy compared to those without
[18–20]. Survival does not appear to be adversely affected
by post-diagnosis pregnancy; however, this may be partially
attributable to a “healthy mother effect” [18, 21, 22]. Few
published studies have examined infant outcomes after a
breast cancer diagnosis [8, 18, 20, 23–25]. Our study exam-
ined the prevalence of PTB, LBW, and SGA according to
breast cancer history (i.e., a personal breast cancer
diagnosis) prior to infant delivery in a population-based
study in North Carolina (NC), and evaluated potential
effect modification by race.
Methods
This study was reviewed and approved by the University
of North Carolina at Chapel Hill’s IRB and Office of
Human Research Ethics (#14-1394).
North Carolina Central Cancer Registry
The primary exposure for this analysis was breast cancer
history prior to infant delivery. We identified breast cancer
diagnoses during the study period (1990–2009) within
the state-mandated North Carolina Central Cancer
Registry (NC-CCR) [26]. The NC-CCR is a gold-certified
North American Association of Central Cancer Registries
(NAACCR) cancer registry within the Centers for Disease
Control and Prevention’s National Program of Cancer
Registries. We used topography site code C50 from the
International Classification of Disease-Oncology third Edi-
tion [27] to identify first primary breast cancer diagnoses at
ages 18–45 years. Additional NC-CCR variables included
date of diagnosis, age at diagnosis, and receipt of treatment
(e.g., surgery, chemotherapy, radiation, endocrine therapy).
North Carolina birth certificate files
The study population for this analysis was comprised of
all live, singleton births to NC residents during 1990–2009
(n = 2,325,229). Within 10 days of a delivery, a hospital
administrator or person attending a non-hospital delivery
(e.g., midwife) must file a birth certificate to the Depart-
ment of Health and Human Services. The NC State Center
for Health Statistics houses and manages these vital statis-
tics records [28]. Further eligibility criteria included mater-
nal ages 18–50 years (n = 2,213,487), and maternal ethnicity
and race designated as non-Hispanic Black or White
(n = 1,916,998). Latinas and other races/ethnicities were ex-
cluded because there was not sufficient power to examine
these racial/ethnic categories independently. Women who
experienced a stillbirth, miscarriage, or other adverse preg-
nancy outcome that did not result in a live birth are not
included because they are not systematically captured in
vital records data. We also excluded mothers who delivered
infants at less than 20 weeks gestation or weighing less than
500 g because they were outside of the age and weight of
viability. After these exclusions, 1,912,269 births contrib-
uted to the LBW analysis, 1,910,014 births contributed to
the PTB analysis (2,255 births were missing gestational
age), and 1,909,748 births contributed to the SGA analysis
(2,521 births were missing gestational age or sex).
Information abstracted from the birth certificate files
included the number of weeks of gestation at time of
delivery, the infant’s weight in pounds and ounces, the
maternal number of years of education, marital status at
time of delivery, number of living children, race, ethnicity,
number of cigarettes smoked per day during pregnancy,
maternal age at delivery, and date of infant delivery.
North Carolina Central Cancer Registry and vital records
linkage
Birth certificate files were linked with the NC-CCR for
the period of 1 January 1990 to 31 December 2009 by
the NC State Center for Health Statistics. The linkage
protocol applied a probabilistic algorithm using names
and social security numbers in Link Plus (Centers for
Disease Control and Prevention; Atlanta, GA, USA).
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Identifying information was redacted from the final
dataset. Breast cancer history prior to infant delivery
was defined as a maternal breast cancer diagnosis re-
corded in the NC-CCR that preceded the date of deliv-
ery in the birth certificate files. Two births by mothers
with a breast cancer history were excluded because the
diagnosis date was not available and the diagnosis age
was above 45 years.
Covariates
The risk of delivering a PTB, LBW, or SGA infant is
known to vary by several maternal characteristics, in-
cluding the age of the mother at the time of pregnancy
and their race/ethnicity and socioeconomic status
(SES) [14, 15, 29–34]. Studies that have focused on dis-
parities in medical treatment and health outcomes
have demonstrated that racial/ethnic and SES dispar-
ities are particularly apparent among cancer patients
[35–39]. Therefore, maternal characteristics, race/ethnicity,
and SES were important covariates to include in the
analytical models of this study. Each covariate included
in the analytical models is described below.
Maternal years of education were categorized as less
than high school (≤11 years), high school diploma (12 years),
at least some or graduated college (13–16 years), and pro-
fessional/graduate degree (≥17 years). The marital status of
the mother was abstracted from the birth certificate
(married or not married). The number of living children
was used to determine parity status as primiparous
(i.e., no infant delivery prior to the current birth) or
multiparous (i.e., a previous delivery in addition to the
current birth). Maternal race/ethnicity is composited
using the race and Hispanic ethnicity variables on the
birth certificate. The number of cigarettes smoked per
day during pregnancy was dichotomized as smoked
during pregnancy (yes/no). The receipt of chemotherapy
is derived from the first listed date of chemotherapy treat-
ment or otherwise categorized as no chemotherapy. The
length of time between diagnosis and infant delivery was
calculated using the breast cancer diagnosis date of the
mother and the date of infant delivery, and categorized
as <2, 2–4.9, and ≥5 years. Maternal age at infant de-
livery (in years) was included in the analysis as a con-
tinuous variable.
Outcomes
Preterm birth was defined as gestational age 20 to <37 weeks
at delivery. Infant weight was calculated by converting
weight in pounds and ounces to grams. Low birthweight
was defined as <2500 g. Small for gestational age was
defined as sex-specific birthweight below the tenth
percentile for a given gestational age. Based on the
continuous measure of birthweight for gestational age
of Oken et al. [40], infant sex, gestational age, and
weight in grams were used to calculate SGA.
Statistical analysis
Multivariable negative log-binomial regression was used
to calculate prevalence ratios (PRs) and 95% confidence
intervals (CIs) for the association between breast cancer
history and birth outcome (i.e., PTB, LBW, and SGA).
We assessed and identified additional covariates as an
effect measure modifier using likelihood ratio tests
(e.g., race/ethnicity) with the a priori significance cri-
teria set at 5% or as a confounder using 5% change in
estimate tests (e.g., maternal age at infant delivery, edu-
cation, marital status, parity, and smoking) for inclusion
in multivariable models. Confounders that met the criteria
for PTB, LBW, or SGA were adjusted for in analyses for
all outcomes. We assessed statistical interaction
between breast cancer history and race on the multiplica-
tive (stratified) scales using cross-product interaction terms
[41]. All analyses were performed using SAS statistical
software version 9.4 (Cary, NC, USA).
Results
Of the 1,912,269 eligible live births in NC during
1990–2009, 512 births were linked to mothers with a
breast cancer history. The mean age at breast cancer
diagnosis was 31.8 years (standard deviation (SD) = 4.7) and
the average time from diagnosis to delivery was 3.3 years
(SD = 2.8). Nearly half (49.4%) of mothers with a breast
cancer history had a record of starting chemotherapy
(Table 1).
Overall, 10.8% of infants were PTB, 8.8% were LBW,
and 11.2% were SGA. Among all births, 72.3% were to
white women and 27.7% to black women. White women
had a higher prevalence of PTB (6.8% vs. 3.9%), LBW
(5.1% vs. 3.7%), and SGA (6.4% vs. 4.7%) compared to
black women (data not shown). About 44.7% of LBW
deliveries to women with a breast cancer history and
46.9% to women without a breast cancer history were
SGA (data not shown). Compared to the general popula-
tion of reproductive age mothers, mothers with a breast
cancer history were older at the time of infant delivery,
and more likely to have attended college, be married,
and not smoke during pregnancy (Table 1).
We observed an increased risk of PTB, LBW, and
SGA for births to women with a breast cancer history,
especially for women who received chemotherapy treat-
ment or gave birth within 2 years of their diagnosis date.
After multivariable adjustment for maternal age, educa-
tion, marital status, parity, race, and smoking, the PR
associated with breast cancer history was 1.67 (95% CI,
1.42–1.97) for PTB, 1.50 (95% CI, 1.23–1.84) for LBW,
and 1.30 (95% CI, 1.05–1.61) for SGA. The PR of PTB
among births to mothers with a breast cancer history
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that received chemotherapy treatment was 2.17 (95% CI,
1.79–2.63) compared to the general population. The cor-
responding PRs were 1.92 (95% CI, 1.50–2.45) for LBW
and 1.63 (95% CI, 1.25–2.13) for SGA. The PR of PTB
among births that occurred within 2 years of the
mother’s diagnosis date was 2.58 (95% CI, 2.12–3.15)
compared to the general population. The corresponding
PRs were 2.16 (95% CI, 1.64–2.85) for LBW and 1.36
(95% CI, 0.96–1.92) for SGA (Table 2).
In analyses stratified according to maternal race, PRs
for the association between breast cancer history and
PTB, LBW, and SGA among black mothers were 1.31
(95% CI, 1.00–1.72), 1.49 (95% CI, 1.14–1.94), and
1.44 (95% CI, 1.11–1.87), respectively. The corresponding
PRs among white mothers were 2.06 (95% CI, 1.67–2.54),
1.53 (95% CI, 1.12–2.08), and 1.10 (95% CI, 0.77–1.58), re-
spectively. The interaction between breast cancer history
and race was statistically significant for associations with
PTB (P interaction = 0.01), but not for LBW (P inter-
action = 0.9) or SGA (P interaction = 0.2).
Compared to white mothers in the general population,
the PRs for PTB were 1.45 (95% CI, 1.44–1.47) for black
mothers without a breast cancer history and 1.90 (95% CI,
1.45–2.50) for black mothers with a breast cancer history.
The PRs for LBW were 1.82 (95% CI, 1.80–1.84) for black
mothers without a breast cancer history, and 2.71
(95% CI, 2.08–3.54) for black mothers with a breast
cancer history. The PRs for SGA were 1.82 (95% CI,
1.80–1.83) for black mothers without a breast cancer
history and 2.62 (95% CI, 2.01–3.40) for black mothers
with a breast cancer history (Table 3).
In analyses restricted to births to women with a breast
cancer history, receipt of chemotherapy was associated
with a PR of 1.78 (95% CI, 1.25–2.53) for PTB, 1.68
(95% CI, 0.94–3.03) for LBW, and 1.72 (95% CI, 0.94–
3.15) for SGA compared to no chemotherapy. The PR of
Table 1 Characteristics of live births according to maternal
breast cancer history at time of delivery, 1990–2009
Breast cancer
history
(n = 512)
General
population
(n = 1,911,757)
n % n %
Preterm birth
Term (≥37 weeks gestation) 404 78.9 1,703,476 89.1
Preterm (<37 weeks gestation) 108 21.1 206,026 10.8
Missing 0 0.0 2255 0.1
Low birthweight
Healthy weight (≥2500 g) 436 85.2 1,743,325 91.2
Low birthweight (<2500 g) 76 14.8 168,432 8.8
Missing 0 0.0 0 0.0
Small for gestational age
Not small for gestational age 444 86.7 1,696,048 88.7
Small for gestational age 68 13.3 213,188 11.2
Missing 0 0.0 2521 0.1
Education
Less than high school (≤11 years) 19 3.7 266,180 13.9
High school diploma (12 years) 123 24.0 662,969 34.7
Some or graduated college
(13–16 years)
282 55.1 814,843 42.6
Professional/graduate degree
(≥17 years)
87 17.0 164,664 8.6
Missing 1 0.2 3101 0.2
Marital status
Married 404 78.9 1,320,768 69.1
Not married 108 21.1 590,559 30.9
Missing 0 0.0 430 0.02
Parity
Primiparous (1 birth) 153 29.9 787,261 41.2
Multiparous (≥2 births) 359 70.1 1,124,496 58.8
Missing 0 0.0 0 0.0
Race/ethnicity
White, non-Hispanic 324 63.3 1,382,978 72.3
Black, non-Hispanic 188 36.7 528,779 27.7
Missing 0 0.0 0 0.0
Smoking
Non-smoker 463 90.4 1,605,661 84.0
Smoker 46 9.0 296,037 15.5
Missing 3 0.6 10,059 0.5
Maternal age at infant delivery (in years)
Mean (standard deviation) 34.6 (4.7) 27.1 (5.7)
Range 20.0–48.0 18.0–50.0
Table 1 Characteristics of live births according to maternal
breast cancer history at time of delivery, 1990–2009 (Continued)
Age at breast cancer diagnosis (in years)
Mean (standard deviation) 31.8 (4.7)
Range 18.7–44.3
Chemotherapy
Did not receive chemotherapy 259 50.6
Received chemotherapy 253 49.4
Missing 0 0.0
Length of time between diagnosis and infant delivery
<2 years 195 38.1
2–4.9 years 197 38.5
≥5 years 120 23.4
Missing 0 0.0
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PTB among births that occurred within 2 years of the
mother’s diagnosis date was 2.19 (95% CI, 1.31–3.67)
compared to births that occurred 5 years or more after
the mother’s diagnosis date. The corresponding PRs
were 1.37 (95% CI, 0.58–3.21) for LBW and 0.89 (95%
CI, 0.47–1.68) for SGA (Table 4).
Discussion
Three population-based studies of birth outcomes of
women diagnosed with breast cancer have been conducted
in Western Australia, Sweden, and Denmark [8, 18, 25].
These studies linked cancer and birth data from nationwide
registries, yet have discordant results. In Western Australia
during 1982–2003, 5% (n = 123) of women with a breast
cancer history conceived after their diagnosis, 50% (n = 62)
of them had a birth within 2 years of their diagnosis date,
and only two PTB (<36 weeks gestation) were reported
[18]. In Sweden during 1973–2002, women with a breast
cancer history (when compared to the general population)
had greater odds of delivering an early PTB (<32 weeks
gestation; adjusted odds ratio (aOR) 3.20, 95% CI, 1.70–
6.03) or very LBW (<1500 g; aOR 2.86, 95% CI, 1.41–5.78)
infant [8]. This increase was not observed in Denmark
during 1973–2002, where the odds of delivering a PTB
(<37 weeks gestation; adjusted prevalence odds ratio
(aPOR) 1.2, 95% CI, 0.4–3.8) or LBW at term (<2500 g
and ≥37 weeks gestation; aPOR 1.3, 95% CI, 0.7–2.2) in-
fant were not significantly different between women with
a breast cancer history and the general population [25].
Compared to our study population that includes 512
births to women with a breast cancer history, the Danish
study [25] had 695 births and the Swedish study [8]
had 331 births to women with a previous breast cancer
diagnosis. Our effect estimates were similar to those
presented in the Danish study [25] and we used the
same cut-off point for PTB, but our effect estimates
Table 2 Age adjusted and multivariable PR and 95% CI for preterm birth, low birthweight, and small for gestational age
Preterm birth (<37 weeks) Low birthweight (<2500 g) Small for gestational age (<10th percentilec)
n Age adjusteda
PR (95% CI)
Multivariableb
PR (95% CI)
n Age adjusteda
PR (95% CI)
Multivariableb
PR (95% CI)
n Age adjusteda
PR (95% CI)
Multivariableb
PR (95% CI)
Breast cancer history
Nod 206,026 1.00 1.00 168,432 1.00 1.00 213,188 1.00 1.00
Yes 108 1.89 (1.60–2.24) 1.67 (1.42–1.97) 76 1.76 (1.43–2.16) 1.50 (1.23–1.84) 68 1.48 (1.19–1.85) 1.30 (1.05–1.61)
Chemotherapy
No 38 1.31 (0.98–1.76) 1.17 (0.87–1.56) 28 1.28 (0.90–1.82) 1.10 (0.78–1.55) 26 1.14 (0.79–1.64) 0.98 (0.68–1.40)
Yes 70 2.48 (2.03–3.03) 2.17 (1.79–2.63) 48 2.24 (1.73–2.89) 1.92 (1.50–2.45) 42 1.83 (1.39–2.40) 1.63 (1.25–2.13)
Time between diagnosis and delivery
<2 years 62 2.86 (2.33–3.52) 2.58 (2.12–3.15) 38 2.29 (1.72–3.04) 2.16 (1.64–2.85) 26 1.43 (1.00–2.04) 1.36 (0.96–1.92)
2–4.9 years 30 1.36 (0.98–1.90) 1.20 (0.86–1.66) 20 1.20 (0.79–1.82) 0.98 (0.65–1.47) 21 1.20 (0.80–1.79) 0.97 (0.66–1.44)
≥5 years 16 1.19 (0.75–1.87) 1.04 (0.66–1.63) 18 1.79 (1.17–2.74) 1.49 (0.98–2.26) 21 2.08 (1.41–3.06) 1.85 (1.27–2.71)
aAdjusted for mother’s age at infant delivery
bAdjusted for mother’s age at infant delivery, education, marital status, parity, race/ethnicity, and smoking
cBirthweight of infant is below the tenth percentile for the infant’s gestational age and sex
dWomen with no breast cancer history serve as the reference group for all comparisons
CI confidence interval, PR prevalence ratio
Table 3 PR and 95% CI for preterm birth, low birthweight, and small for gestational age stratified by race/ethnicity
Race/ethnicity Breast
cancer
history
Preterm birtha (<37 weeks) Low birthweighta (<2500 g) Small for gestational agea (<10th percentilec)
n PR (95% CI)b n PR (95% CI)b n PR (95% CI)b
Black, non-Hispanic No 75,286 1.00 71,159 1.00 90,006 1.00
Yes 40 1.31 (1.00–1.72) 41 1.49 (1.14–1.94) 41 1.44 (1.11–1.87)
White, non-Hispanic No 130,740 1.00 97,273 1.00 123,182 1.00
Yes 68 2.06 (1.67–2.54) 35 1.53 (1.12–2.08) 27 1.10 (0.77–1.58)
Black, non-Hispanicd No 75,286 1.45 (1.44–1.47) 71,159 1.82 (1.80–1.84) 90,006 1.82 (1.80–1.83)
Yes 40 1.90 (1.45–2.50) 41 2.71 (2.08–3.54) 41 2.62 (2.01–3.40)
aP interaction of race/ethnicity and breast cancer history is 0.01 for preterm birth, 0.9 for low birthweight, and 0.2 for small for gestational age
bAdjusted for mother’s age at infant delivery, education, marital status, parity, and smoking
cBirthweight of infant is below the tenth percentile for the infant’s gestational age and sex
dWhite women with no breast cancer history serve as the reference group for these comparisons
CI confidence interval, PR prevalence ratio
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were statistically significant. The Swedish study [8]
used lower cut-off points for PTB and LBW. We re-
analyzed our data using the same cut-off points as the
Swedish study [8], but our results were not statistically
significant. The Danish study [25] conducted stratified
analyses by sex of child and type of treatment, but did
not see a substantial change in the overall effect estimates.
Our analysis reinforces that the racial group is an import-
ant consideration for evaluating adverse birth outcomes in
the USA.
Examination of the prevalence of adverse birth outcomes
within race showed that both black and white mothers with
a breast cancer history had a significant increase in risk
(31–49% and 10–106%, respectively) of delivering a PTB,
LBW, or SGA infant compared to mothers without a breast
cancer history within their racial group. Yet, the prevalence
ratios of PTB and LBW were higher for white mothers
compared to black mothers in these analyses. This may be
due, in part, to the cumulative exposure to risk factors for
PTB and LBW [42, 43] influencing the health status of
black women such that the added health implications of
being diagnosed and treated for breast cancer does not have
the same level of effect on their reproductive health out-
comes as it does for white women. When white mothers in
the general population are used as the common referent,
white mothers with a breast cancer history have the highest
prevalence ratio of PTB, but black mothers with a breast
cancer history have the highest prevalence ratio of LBW
and SGA. The interaction between breast cancer history
and race was significant on the multiplicative scale in the
within-race analyses when examining PTB. These results
attest to the importance of examining disparities in adverse
birth outcomes within racial groups, instead of solely using
the white unexposed group as the reference for all compari-
son groups [44].
Some limitations of our analysis must be considered.
Information on breast cancer hormone receptor status,
stage, use of endocrine therapy, and chemotherapy agents,
dose, and cycle were either not available or frequently
missing and therefore not analyzed. Samples sizes were
small, with correspondingly limited statistical power in
subgroup analyses. Misclassification of the breast cancer
history status of the mother was more likely to occur
among births that occurred early in our 1990–2009 study
period since breast cancer diagnoses prior to 1990 were
not included in the data. This misclassification may be
largest among women with more than 5 years between
their breast cancer diagnosis and infant delivery dates. We
were not able to account for multiple births to the same
mother. Pregnancies that result from assisted reproductive
technology (ART) cannot be identified and tend to have a
higher prevalence of multiple births, as well as PTB and
LBW deliveries. Only about 1.5% of infants born in the
USA general population are conceived via ART [45].
The strengths of our analysis include the use of a
population-based dataset to address a 20-year period
with approximately two million births overall. With
persistent racial disparities in cancer and birth out-
comes in the USA, the added exploration of race as a
modifier of the association between breast cancer history
Table 4 PR and 95% CI for preterm birth, low birthweight, and small for gestational age in women with a breast cancer history
Preterm birth (<37 weeks) Low birthweight (<2500 g) Small for gestational age
(<10th percentilec)
n Age adjusteda
PR (95% CI)
Multivariableb
PR (95% CI)
n Age adjusteda
PR (95% CI)
Multivariableb
PR (95% CI)
n Age adjusteda
PR (95% CI)
Multivariableb
PR (95% CI)
Chemotherapy
No 38 1.00 1.00 28 1.00 1.00 26 1.00 1.00
Yes 70 1.86 (1.31–2.64) 1.78 (1.25–2.53) 48 1.85 (1.21–2.83) 1.68 (0.94–3.03) 42 1.80 (1.13–2.85) 1.72 (0.94–3.15)
Time between diagnosis and delivery
<2 years 62 2.24 (1.34–3.74) 2.19 (1.31–3.67) 38 1.47 (0.87–2.51) 1.37 (0.58–3.21) 26 0.88 (0.51–1.53) 0.89 (0.47–1.68)
2–4.9 years 30 1.11 (0.63–1.95) 1.11 (0.63–1.96) 20 0.73 (0.40–1.33) 0.68 (0.28–1.64) 21 0.66 (0.38–1.17) 0.57 (0.30–1.08)
≥5 years 16 1.00 1.00 18 1.00 1.00 21 1.00 1.00
Race/ethnicity
White, non-Hispanic 68 1.00 1.00 35 1.00 1.00 27 1.00 1.00
Black, non-Hispanic 40 1.00 (0.71–1.42) 0.97 (0.65–1.45) 41 2.02 (1.33–3.05) 1.76 (1.08–2.86) 41 2.60 (1.66–4.08) 2.55 (1.53–4.24)
Parity
Primiparous (1 birth) 28 1.00 1.00 22 1.00 1.00 21 1.00 1.00
Multiparous (≥2 births) 80 1.27 (0.86–1.86) 1.10 (0.74–1.64) 54 1.09 (0.69–1.72) 0.78 (0.47–1.27) 47 0.94 (0.58–1.51) 0.80 (0.48–1.32)
aAdjusted for mother’s age at infant delivery
bAdjusted for mother’s age at infant delivery, education, marital status, parity, race/ethnicity, and smoking
cBirthweight of infant is below the tenth percentile for the infant’s gestational age and sex
CI confidence interval, PR prevalence ratio
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and adverse birth outcomes is an important contribution.
Our analyses that examined receipt of chemotherapy and
time between diagnosis date and delivery provide add-
itional insights into factors along the breast cancer tra-
jectory that may contribute to increased risk of adverse
birth outcomes among mothers with a breast cancer
history. However, we are unable to disentangle the in-
fluence of chemotherapy and time since diagnosis since
women who gave birth within 2 years of their diagnosis
date were slightly more likely to have received chemo-
therapy (54.9% received chemotherapy and 45.1% did
not) than women who gave birth 2 or more years after
their diagnosis date (46.1% received chemotherapy and
53.9% did not). In our data, it is also not possible to
distinguish pregnancies that co-occur with breast cancer
diagnosis or the active treatment period. Future longi-
tudinal studies that follow breast cancer patients from
diagnosis to birth will be critical to disentangle poten-
tial differences between women who are diagnosed with
breast cancer during pregnancy from those who con-
ceive after the active treatment period.
Conclusions
Women with a premenopausal breast cancer diagnosis
may not have started or completed their families at the
time of diagnosis. Our findings indicate that a breast
cancer history may correspond to 30–67% increases in
risk of delivering a PTB, LBW, or SGA infant compared
to the general population, with greater increases in risk
observed among women who received chemotherapy or
gave birth within 2 years of diagnosis.
Breast cancer treatment has long-term implications
on the health and quality of life of women. Under-
standing the effects of breast cancer treatment on
future reproductive health outcomes is an important
concern for premenopausal women. They may benefit
from targeted preconception health services and re-
productive health counseling prior to and after cancer
treatment. Furthermore, qualitative research may re-
veal a deeper understanding of the decision-making
process of breast cancer survivors regarding their
treatment regimen as it relates to their post-treatment
childbearing goals.
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